Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Rudragouda Channappanavar, Stanley Perlman, Rudragouda Channappanavar, Stanley Perlman

Abstract

Human coronaviruses (hCoVs) can be divided into low pathogenic and highly pathogenic coronaviruses. The low pathogenic CoVs infect the upper respiratory tract and cause mild, cold-like respiratory illness. In contrast, highly pathogenic hCoVs such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) predominantly infect lower airways and cause fatal pneumonia. Severe pneumonia caused by pathogenic hCoVs is often associated with rapid virus replication, massive inflammatory cell infiltration and elevated pro-inflammatory cytokine/chemokine responses resulting in acute lung injury (ALI), and acute respiratory distress syndrome (ARDS). Recent studies in experimentally infected animal strongly suggest a crucial role for virus-induced immunopathological events in causing fatal pneumonia after hCoV infections. Here we review the current understanding of how a dysregulated immune response may cause lung immunopathology leading to deleterious clinical manifestations after pathogenic hCoV infections.

Keywords: Cytokine storm; Immunopathology; Interferon; MERS-CoV; Monocyte-macrophage; SARS-CoV.

Figures

Fig. 1
Fig. 1
Staining for SARS-CoV-N antigen in lungs of C57BL/6 and BALB/c mice at 16 and 48 h post-infection
Fig. 2
Fig. 2
Schematic representation of protective versus pathogenic inflammatory responses to pathogenic hCoV infections

References

    1. Masters PS, Perlman, S (2013) Coronaviridae. In: Knipe DM, Howley P (eds) Fields Virology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 825–858
    1. Siddell SZJ, Snijder EJ. Coronaviruses, toroviruses, and arteriviruses, vol. 1. London: Hodder Arnold; 2005.
    1. Peck KM, et al. Coronavirus host range expansion and Middle East respiratory syndrome coronavirus emergence: biochemical mechanisms and evolutionary perspectives. Annu Rev Virol. 2015;2(1):95–117. doi: 10.1146/annurev-virology-100114-055029.
    1. Su S, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi: 10.1016/j.tim.2016.03.003.
    1. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69(4):635–664. doi: 10.1128/MMBR.69.4.635-664.2005.
    1. Heugel J, et al. Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Dis J. 2007;26(8):753–755. doi: 10.1097/INF.0b013e318054e31b.
    1. Kuypers J, et al. Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics. 2007;119(1):e70–e76. doi: 10.1542/peds.2006-1406.
    1. Drosten C, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976. doi: 10.1056/NEJMoa030747.
    1. Kuiken T, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263–270. doi: 10.1016/S0140-6736(03)13967-0.
    1. Peiris JS, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319–1325. doi: 10.1016/S0140-6736(03)13077-2.
    1. van Boheemen S et al (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3(6)
    1. Zaki AM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. doi: 10.1056/NEJMoa1211721.
    1. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439–450. doi: 10.1038/nrmicro2147.
    1. WHO Cumulative number of reported probable cases of SARS. In: 2003
    1. WUoM-CTfAtHaIRfA-RGLaoMAf
    1. WHO: Middle East respiratory syndrome coronavirus (MERS-CoV).
    1. Adney DR, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis. 2014;20(12):1999–2005. doi: 10.3201/eid2012.141280.
    1. Alagaili AN, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio. 2014;5(2):e00884–e00814. doi: 10.1128/mBio.00884-14.
    1. Ge XY, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535–538. doi: 10.1038/nature12711.
    1. Menachery VD, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21(12):1508–1513. doi: 10.1038/nm.3985.
    1. Arabi YM, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389–397. doi: 10.7326/M13-2486.
    1. Assiri A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–761. doi: 10.1016/S1473-3099(13)70204-4.
    1. Leong HN, et al. Clinical and laboratory findings of SARS in Singapore. Ann Acad Med Singap. 2006;35(5):332–339.
    1. Saad M, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–306. doi: 10.1016/j.ijid.2014.09.003.
    1. Al-Tawfiq JA, et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis. 2014;59(2):160–165. doi: 10.1093/cid/ciu226.
    1. Zumla A, et al. Middle East respiratory syndrome. Lancet. 2015;386(9997):995–1007. doi: 10.1016/S0140-6736(15)60454-8.
    1. Peiris JS, et al. Severe acute respiratory syndrome. Nat Med. 2004;10(12 Suppl):S88–S97. doi: 10.1038/nm1143.
    1. Peiris JS, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767–1772. doi: 10.1016/S0140-6736(03)13412-5.
    1. Nicholls J, et al. SARS: clinical virology and pathogenesis. Respirology. 2003;8(Suppl):S6–S8. doi: 10.1046/j.1440-1843.2003.00517.x.
    1. van den Brand JM, et al. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol. 2014;151(1):83–112. doi: 10.1016/j.jcpa.2014.01.004.
    1. Gu J, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–424. doi: 10.1084/jem.20050828.
    1. Nicholls JM, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361(9371):1773–1778. doi: 10.1016/S0140-6736(03)13413-7.
    1. van den Brand JM et al (2014) The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol 151(1):83–112
    1. Cui W, et al. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003;37(6):857–859. doi: 10.1086/378587.
    1. Li T, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004;189(4):648–651. doi: 10.1086/381535.
    1. Wang YH, et al. A cluster of patients with severe acute respiratory syndrome in a chest ward in southern Taiwan. Intensive Care Med. 2004;30(6):1228–1231. doi: 10.1007/s00134-004-2311-8.
    1. Ng DL, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186(3):652–658. doi: 10.1016/j.ajpath.2015.10.024.
    1. Channappanavar R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–193. doi: 10.1016/j.chom.2016.01.007.
    1. Davidson S, et al. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interf Cytokine Res. 2015;35(4):252–264. doi: 10.1089/jir.2014.0227.
    1. Shaw AC, et al. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. 2013;13(12):875–887. doi: 10.1038/nri3547.
    1. Cheung CY, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819–7826. doi: 10.1128/JVI.79.12.7819-7826.2005.
    1. Law HK, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–2374. doi: 10.1182/blood-2004-10-4166.
    1. Yen YT, et al. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006;80(6):2684–2693. doi: 10.1128/JVI.80.6.2684-2693.2006.
    1. Chien JY, et al. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology. 2006;11(6):715–722. doi: 10.1111/j.1440-1843.2006.00942.x.
    1. Wang CH, et al. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respir Res. 2005;6:42. doi: 10.1186/1465-9921-6-42.
    1. Wong CK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. doi: 10.1111/j.1365-2249.2004.02415.x.
    1. Zhang Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410–4415. doi: 10.1128/IAI.72.8.4410-4415.2004.
    1. Cameron MJ, et al. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2008;133(1):13–19. doi: 10.1016/j.virusres.2007.02.014.
    1. Cameron MJRL, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller MP, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y, Seneviratne C, Bosinger SE, Persad D, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ, Kelvin DJ. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81(16):8692–8706. doi: 10.1128/JVI.00527-07.
    1. Huang KJ, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185–194. doi: 10.1002/jmv.20255.
    1. Theron M, et al. A probable role for IFN-gamma in the development of a lung immunopathology in SARS. Cytokine. 2005;32(1):30–38. doi: 10.1016/j.cyto.2005.07.007.
    1. Lau SK, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. 2013;94(Pt 12):2679–2690. doi: 10.1099/vir.0.055533-0.
    1. Chu H et al (2015) Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis 213(6):904–14
    1. Tynell J, et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J Gen Virol. 2016;97(2):344–355. doi: 10.1099/jgv.0.000351.
    1. Zhou J, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis. 2014;209(9):1331–1342. doi: 10.1093/infdis/jit504.
    1. Scheuplein VA, et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol. 2015;89(7):3859–3869. doi: 10.1128/JVI.03607-14.
    1. Kim ES, et al. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci. 2016;31(11):1717–1725. doi: 10.3346/jkms.2016.31.11.1717.
    1. Min CK, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6:25359. doi: 10.1038/srep25359.
    1. Roberts A, et al. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol. 2005;79(9):5833–5838. doi: 10.1128/JVI.79.9.5833-5838.2005.
    1. Day CW, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395(2):210–222. doi: 10.1016/j.virol.2009.09.023.
    1. Nagata N, et al. Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am J Pathol. 2008;172(6):1625–1637. doi: 10.2353/ajpath.2008.071060.
    1. Roberts A, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 2007;3(1):e5. doi: 10.1371/journal.ppat.0030005.
    1. Frieman MB, et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 2010;6(4):e1000849. doi: 10.1371/journal.ppat.1000849.
    1. Zhao J, et al. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011;121(12):4921–4930. doi: 10.1172/JCI59777.
    1. Graham RL, et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med. 2012;18(12):1820–1826. doi: 10.1038/nm.2972.
    1. Rockx B, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol. 2009;83(14):7062–7074. doi: 10.1128/JVI.00127-09.
    1. Smits SL, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010;6(2):e1000756. doi: 10.1371/journal.ppat.1000756.
    1. Totura AL, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. MBio. 2015;6(3):e00638–e00615. doi: 10.1128/mBio.00638-15.
    1. Jimenez-Guardeno JM, et al. The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS Pathog. 2014;10(8):e1004320. doi: 10.1371/journal.ppat.1004320.
    1. Nieto-Torres JL, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014;10(5):e1004077. doi: 10.1371/journal.ppat.1004077.
    1. Nieto-Torres JL, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015;485:330–339. doi: 10.1016/j.virol.2015.08.010.
    1. de Wit E, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110(41):16598–16603. doi: 10.1073/pnas.1310744110.
    1. Haagmans BL, et al. Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J Virol. 2015;89(11):6131–6135. doi: 10.1128/JVI.00661-15.
    1. Houser KV, et al. Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. J Infect Dis. 2016;213(10):1557–1561. doi: 10.1093/infdis/jiw080.
    1. Falzarano D, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10(8):e1004250. doi: 10.1371/journal.ppat.1004250.
    1. Johnson RF, et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology. 2015;485:422–430. doi: 10.1016/j.virol.2015.07.013.
    1. Barlan A, et al. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J Virol. 2014;88(9):4953–4961. doi: 10.1128/JVI.00161-14.
    1. Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970–4975. doi: 10.1073/pnas.1323279111.
    1. Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol. 2015;13:123–129. doi: 10.1016/j.coviro.2015.06.009.
    1. van Doremalen N, Munster VJ. Animal models of Middle East respiratory syndrome coronavirus infection. Antivir Res. 2015;122:28–38. doi: 10.1016/j.antiviral.2015.07.005.
    1. Pascal KE, et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2015;112(28):8738–8743. doi: 10.1073/pnas.1510830112.
    1. Cockrell A et al (2016) A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nature Microbiology 2:16226
    1. Li K et al (2017) Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proceedings of the National Academy of Sciences 114(15):E3119–E3128
    1. Frieman M, et al. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol. 2007;81(18):9812–9824. doi: 10.1128/JVI.01012-07.
    1. Kindler E, et al. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv Virus Res. 2016;96:219–243. doi: 10.1016/bs.aivir.2016.08.006.
    1. Narayanan K, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471–4479. doi: 10.1128/JVI.02472-07.
    1. Sun L, et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One. 2012;7(2):e30802. doi: 10.1371/journal.pone.0030802.
    1. Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev. 2008;19(2):121–132. doi: 10.1016/j.cytogfr.2008.01.001.
    1. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Current Opinion in Virology. 2012;2(3):264–275. doi: 10.1016/j.coviro.2012.04.004.
    1. Wathelet MG, et al. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol. 2007;81(21):11620–11633. doi: 10.1128/JVI.00702-07.
    1. Fehr AR et al (2016) The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection. mBio 7(6):e01721–16
    1. Frieman M, et al. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol. 2009;83(13):6689–6705. doi: 10.1128/JVI.02220-08.
    1. Kopecky-Bromberg SA, et al. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81(2):548–557. doi: 10.1128/JVI.01782-06.
    1. Lu XL, et al. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes. 2011;42(1):37–45. doi: 10.1007/s11262-010-0544-x.
    1. Siu KL, et al. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol. 2014;11(2):141–149. doi: 10.1038/cmi.2013.61.
    1. Lui PY, et al. Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerg Microbes Infect. 2016;5:e39. doi: 10.1038/emi.2016.33.
    1. Yang Y, et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. 2013;4(12):951–961. doi: 10.1007/s13238-013-3096-8.
    1. Chu CM, et al. Initial viral load and the outcomes of SARS. CMAJ. 2004;171(11):1349–1352. doi: 10.1503/cmaj.1040398.
    1. Ng ML, et al. Proliferative growth of SARS coronavirus in Vero E6 cells. J Gen Virol. 2003;84(Pt 12):3291–3303. doi: 10.1099/vir.0.19505-0.
    1. Oh MD, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med. 2016;375(13):1303–1305. doi: 10.1056/NEJMc1511695.
    1. Herold S, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med. 2008;205(13):3065–3077. doi: 10.1084/jem.20080201.
    1. Hogner K, et al. Macrophage-expressed IFN-beta contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog. 2013;9(2):e1003188. doi: 10.1371/journal.ppat.1003188.
    1. Rodrigue-Gervais IG, et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. Cell Host Microbe. 2014;15(1):23–35. doi: 10.1016/j.chom.2013.12.003.
    1. Zhao J, et al. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318–9325. doi: 10.1128/JVI.01049-10.
    1. Kim KD, et al. Adaptive immune cells temper initial innate responses. Nat Med. 2007;13(10):1248–1252. doi: 10.1038/nm1633.
    1. Palm NW, Medzhitov R. Not so fast: adaptive suppression of innate immunity. Nat Med. 2007;13(10):1142–1144. doi: 10.1038/nm1007-1142b.
    1. Zornetzer GA, et al. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol. 2010;84(21):11297–11309. doi: 10.1128/JVI.01130-10.
    1. Page C, et al. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol. 2012;86(24):13334–13349. doi: 10.1128/JVI.01689-12.
    1. Gralinski LE, et al. Genome wide identification of SARS-CoV susceptibility loci using the collaborative cross. PLoS Genet. 2015;11(10):e1005504. doi: 10.1371/journal.pgen.1005504.
    1. Drosten C, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2013;13(9):745–751. doi: 10.1016/S1473-3099(13)70154-3.
    1. Lew TW, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):374–380. doi: 10.1001/jama.290.3.374.
    1. Jiang Y, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005;171(8):850–857. doi: 10.1164/rccm.200407-857OC.
    1. Reghunathan R et al (2005) Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunology 6:2
    1. Stockman LJ, et al. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi: 10.1371/journal.pmed.0030343.
    1. Al-Tawfiq JA, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42–46. doi: 10.1016/j.ijid.2013.12.003.
    1. Falzarano D, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317. doi: 10.1038/nm.3362.
    1. Omrani AS, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095. doi: 10.1016/S1473-3099(14)70920-X.
    1. Auyeung TW, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51(2):98–102. doi: 10.1016/j.jinf.2004.09.008.
    1. Ho JC, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003;168(12):1449–1456. doi: 10.1164/rccm.200306-766OC.
    1. Yam LY, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007;54(1):28–39. doi: 10.1016/j.jinf.2006.01.005.
    1. Haagmans BL, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10(3):290–293. doi: 10.1038/nm1001.
    1. Zumla A et al (2016) Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15(5):327–47
    1. Davidson S, et al. IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. EMBO Mol Med. 2016;8(9):1099–1112. doi: 10.15252/emmm.201606413.
    1. Blazek K, et al. IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production. J Exp Med. 2015;212(6):845–853. doi: 10.1084/jem.20140995.
    1. Imai Y, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235–249. doi: 10.1016/j.cell.2008.02.043.
    1. Shirey KA, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497(7450):498–502. doi: 10.1038/nature12118.
    1. Teijaro JR, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980–991. doi: 10.1016/j.cell.2011.08.015.
    1. Walsh KB, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108(29):12018–12023. doi: 10.1073/pnas.1107024108.
    1. Leuschner F, et al. Silencing of CCR2 in myocarditis. Eur Heart J. 2015;36(23):1478–1488. doi: 10.1093/eurheartj/ehu225.
    1. Leuschner F, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29(11):1005–1010. doi: 10.1038/nbt.1989.
    1. Darwish I, et al. Immunomodulatory therapy for severe influenza. Expert Rev Anti-Infect Ther. 2011;9(7):807–822. doi: 10.1586/eri.11.56.
    1. McDermott JE, et al. The effect of inhibition of PP1 and TNFalpha signaling on pathogenesis of SARS coronavirus. BMC Syst Biol. 2016;10(1):93. doi: 10.1186/s12918-016-0336-6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe